Skip Navigation

Cardiovascular Research 1998 39(3):665-673; doi:10.1016/S0008-6363(98)00152-7
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Horowitz, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Horowitz, J. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist

Yi Zhanga, John R. Oliverb and John D. Horowitza,*

aCardiology Unit, The Queen Elizabeth Hospital, University of Adelaide, 28 Woodville Road, Woodville South, SA 5011, Australia
bEndocrinology Unit, Flinders Medical Centre, Bedford Park, SA 5042, Australia

* Corresponding author. Tel.: +61-8-8222-6725; Fax: +61-8-8222-6030.

Objective: The vasoconstrictor effect of endothelins (ET) is mediated by endothelin A (ETA) and endothelin B (ETB) receptors. Furthermore, ETB receptor stimulation results in release of vasodilators. Hence, ETA receptor antagonists should attenuate ET-mediated vasoconstriction. The aim of the present study was to evaluate and compare the effects of BQ-123, an ETA receptor antagonist, and bosentan, an ETA and ETB receptor antagonist, on coronary vasomotor tone, left ventricular systolic function and ET-1 efflux in the presence or absence of myocardial ischaemia/reperfusion. Methods: Isolated rat hearts were perfused using a Langendorff preparation. Global ischaemia was induced on average by 68±2% (±standard error of the mean) reduction of a baseline perfusion flow-rate 10 min after introduction of ET antagonists. Thirty minutes of ischaemia was followed by 30 min reperfusion. ET-1 efflux in coronary perfusate was measured by radioimmunoassay. Results: In non-ischaemic hearts (n=7), BQ-123 (10–6 M) perfusion induced a progressive decrease in coronary flow-rate compared with control group. This flow reduction persisted after wash-out of BQ-123. In contrast, bosentan (10–5 M, n=7) induced no change in perfusion rate. In the absence of ET antagonists (n=16), there was a 22±6% post-ischaemic increase in perfusion flow-rate. BQ-123 (n=5) but not bosentan (n=12) abolished this post-ischaemic increase in flow-rate. Neither BQ-123 nor bosentan induced significant variation in force of contraction. In ischaemic hearts, ischaemia per se induced a transient decrease in force of contraction. Bosentan significantly (P<0.05) accentuated and BQ-123 tended to accentuate (P=0.06) this decrease in force of contraction during ischaemia. Bosentan but not BQ-123 significantly impaired the recovery of systolic function during reperfusion (P<0.05). Both BQ-123 and bosentan perfusion increased ET-1 efflux rate to 730±188% and 315±81% respectively. This effect was abolished during ischaemia for BQ-123, but not for bosentan. Conclusions: In isolated perfused rat hearts, both BQ-123 and bosentan increased ET-1 efflux, but only BQ-123 exerted vasoconstrictor effects. These results thus generated the hypothesis that: (1) ET-1 release within the coronary vascular bed may be physiologically subject to negative feedback regulation mediated via ETA receptors; (2) ETA receptor antagonists increase ET-1 efflux, which may lead to net vasoconstriction via unopposed ETB stimulation. Furthermore, the negative inotropic effects observed during ischaemia suggest that ET is critical to the maintenance of systolic function during ischaemia.

KEYWORDS Isolated rat heart; Ischaemia; Endothelin; Endothelin receptor antagonists; Cardiac force of contraction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Kusmic, G. Lazzerini, F. Coceani, R. Barsacchi, A. L'Abbate, and G. Sambuceti
Paradoxical coronary microcirculatory constriction during ischemia: a synergic function for nitric oxide and endothelin
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1814 - H1821.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
S. Zaedi, S. Jesmin, N. Yamaguchi, N. Shimojo, S. Maeda, S. Gando, I. Yamaguchi, K. Goto, and T. Miyauchi
Altered expression of endothelin, vascular endothelial growth factor, and its receptor in hepatic tissue in endotoxemic rat.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1182 - 1186.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. V Agapitov and W. G Haynes
Role of endothelin in cardiovascular disease
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 1 - 15.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.